Surgical resection and radiofrequency ablation in the treatment of hepatocellular carcinoma

Xiaosan Fang; Siyi Xu

doi:10.1117/12.2691872

7 September 2023 Surgical resection and radiofrequency ablation in the treatment of hepatocellular carcinoma

Xiaosan Fang, Siyi Xu

Proceedings Volume 12789, International Conference on Modern Medicine and Global Health (ICMMGH 2023); 127890A (2023) https://doi.org/10.1117/12.2691872
Event: International Conference on Modern Medicine and Global Health (ICMMGH 2023), 2023, Oxford, United Kingdom

Abstract

Primary liver cancer has a high degree of malignancy and a high incidence rate in China, ranking second in the incidence rate of malignant tumors. Its high incidence rate is mostly related to chronic hepatitis B infection, hepatitis C, alcoholic cirrhosis, etc. Some studies have shown that the positive status of virus detection in patients with chronic hepatitis B-related hepatocellular carcinoma (HCC) after surgery can promote tumor recurrence and reduce the survival rate. According to the tumor size, liver cancer can be divided into four types: first, micro liver cancer, which means that the tumor diameter is less than 2 cm. Second, small liver cancer, which means that the tumor diameter is between 2 and 5 cm. Third, large liver cancer refers to tumors with a diameter of more than 5 cm but less than 10 cm. Fourth, huge liver cancer, which means that the tumor diameter is 10 cm and above. In recent years, the incidence rate of primary liver cancer has gradually increased, which seriously threatens the life safety of patients. This paper reviews and analyzes the surgical resection (SR), laparoscopic hepatectomy (LH), radiofrequency ablation (RFA), and lumbar medial branch nerve radiofrequency ablation (LRFA) in the treatment of HCC. It can be concluded that RFA and LH turn out to be typically safe and effective HCC treatment, which help improve the prognosis of HCC patients.

Citation Download Citation

Xiaosan Fang and Siyi Xu "Surgical resection and radiofrequency ablation in the treatment of hepatocellular carcinoma", Proc. SPIE 12789, International Conference on Modern Medicine and Global Health (ICMMGH 2023), 127890A (7 September 2023); https://doi.org/10.1117/12.2691872

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available